LAUSR

Due to the lack of information on bioavailability and toxicity of modified mycotoxins, current risk assessment on these modified forms assumes an identical toxicity of the modified form to their respective unmodified counterparts. Crossover animal trials were performed with intravenous and oral administration of T-2 toxin (T-2) and T-2 toxin-3α-glucoside (T2-G) to broiler chickens. Plasma concentrations of T2-G, T-2, and main phase I metabolites were quantified using a validated liquid chromatography-tandem mass spectrometry method with a limit of quantitation for all compounds of 0.1 ng/mL. Resulting plasma concentration-time profiles were processed via two-compartmental toxicokinetic models. No T-2 triol and only traces of HT-2 were detected in the plasma samples after both intravenous and oral administration. The results indicate that T-2 has a low absolute oral bioavailability of 2.17 ± 1.80%. For T2-G, an absorbed fraction of the dose and absolute oral bioavailability of 10.4 ± 8.7% and 10.1 ± 8.5% were observed, respectively. This slight difference is caused by a minimal (and neglectable) presystemic hydrolysis of T2-G to T-2, that is, 3.49 ± 1.19%. Although low, the absorbed fraction of T2-G is 5 times higher than that of T-2. These differences in toxicokinetics parameters between T-2 and T2-G clearly indicate the flaw in assuming equal bioavailability and/or toxicity of modified and free mycotoxins in current risk assessments.